TICKERNERD
Menu
SGPHealthcare · Biotechnology

SGP Stock Forecast: SpyGlass Pharma, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$34
0.00% on the day

The 6 Wall Street analysts covering SpyGlass Pharma, Inc. hold a median 12-month price target of $42 — +21.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 3 of 100 as at 4 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.2B
Ticker Nerd rank
3/ 100
Median analyst target
$42
Analysts covering
6
Revenue$0.0
Operating income−$22.0M
Net income−$19.9M
Free cash flow−$16.8M
Quarterly, 7 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.8%
1M
+38.2%
From high
0.0%
From low
+96.2%
$18
$34
Range since 6 Feb 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

SGP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores SpyGlass Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
3/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
48
Size
42
Momentum
32
Issuance
12
Growth
8
Accruals
8
Value
7
Volatility
4
Quality
2

Revisions (48): Analysts have, on balance, been raising their forecasts.

Quality (2): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SGP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SGP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 6 Feb 2026Adjusted close, US dollars
$20$30$40$50$60Apr 26Jul 26Oct 26SGPHigh $62Median $42Low $37

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $37Median $42High $62

The green dot is the last close — the median target sits +21.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 Oct 2026HC Wainwright & Co.ReiteratesBuy$37
5 Oct 2026HC Wainwright & Co.ReiteratesBuy$37
5 Oct 2026HC Wainwright & Co.ReiteratesBuy—
14 Aug 2026Raymond JamesInitiatesOutperform—
14 Aug 2026Raymond JamesInitiatesOutperform$39
10 Mar 2026HC Wainwright & Co.InitiatesBuy—
10 Mar 2026HC Wainwright & Co.InitiatesBuy$37
3 Mar 2026CitigroupInitiatesBuy—
3 Mar 2026CitigroupInitiatesBuy$42
3 Mar 2026JefferiesInitiatesBuy$62
3 Mar 2026JefferiesInitiatesBuy—
3 Mar 2026Leerink PartnersInitiatesOutperform$42
3 Mar 2026Leerink PartnersInitiatesOutperform—
3 Mar 2026StifelInitiatesBuy$42
3 Mar 2026StifelInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

SGP appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SGP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

SGP vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Apr 26Jul 26Oct 26SGPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SGP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

SpyGlass Pharma, Inc. (SGP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−27.6×

Cheaper than 97% of US stocks

Price / sales
—
Price / book
5.0×

Cheaper than 19% of US stocks

EV / EBITDA
−15.1×

Cheaper than 88% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
40.3%

Higher than 91% of US stocks

Return on assets
−34.4%

Higher than 12% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

SpyGlass Pharma, Inc. (SGP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • SpyGlass Pharma, Inc. has a market value of $1.2B and an enterprise value of $919.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$56.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$49.7M.

  • Shares outstanding: 33.4M.

  • Trailing P/E: −27.6×; forward P/E: −12.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • SpyGlass Pharma, Inc. employs 76 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

SGP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SGPSpyGlass Pharma, Inc.$1.2B3
SPTXSeaport Therapeutics, Inc.$1.1B15
VORVor Biopharma, Inc.$1.2B24
VSTMVerastem, Inc.$1.2B63
JANXJanux Therapeutics, Inc.$1.1B78
MNKDMannKind Corp.$1.2B38
AVLNAvalyn Pharma, Inc.$1.2B1

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own SpyGlass Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SGP news & analysis

SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System

GlobeNewsWire · 19 Oct 2026positive

SpyGlass Pharma reported positive four-year results from its first-in-human trial of the BIM-IOL System in patients with mild-to-moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery. The company reported a 37% mean IOP reduction, 86% of patients remaining off topical IOP-lowering drops, 90% maintaining at least 20/25 visual acuity, and no product-related adverse events.

Why it matters — The long-term trial results provide updates on the system’s reported safety and efficacy in reducing eye pressure and reliance on topical drops.

SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability

GlobeNewsWire · 1 Oct 2026positive

SpyGlass Pharma announced the acquisition of all outstanding shares of Advanced Vision Science, Inc. (AVS), an ophthalmic medical device company manufacturing intraocular lenses and lens materials, for approximately $13 million in cash. AVS, a Santen subsidiary and current supplier of SpyGlass Pharma's IOL for its two Phase 3 trials of the BIM-IOL System, provides scalable commercial IOL manufacturing capacity.

Why it matters — This acquisition secures scalable commercial IOL manufacturing capacity and advances SpyGlass Pharma's lens portfolio expansion capability, which is relevant given AVS supplies the IOL used in its Phase 3 registrational trials.

SpyGlass Pharma, Inc. (SGP) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha · 10 Sept 2026neutral

SpyGlass Pharma, Inc. presented at Citigroup's Biopharma Back to School Summit 2026, with a transcript of the presentation published by Seeking Alpha. No specific details from the event were included beyond the presentation occurring.

Why it matters — SGP watchers would care because a presentation at a major investment bank's biopharma conference offers the company a platform to communicate its story to investors.

SpyGlass Pharma to Participate in Upcoming Investor Conferences

GlobeNewsWire · 2 Sept 2026neutral

SpyGlass Pharma, Inc. announced that members of its executive management team will participate in two upcoming investor conferences: the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026, featuring 1x1 meetings only, and Citi's 2026 Biopharma Back to School Conference on September 10, 2026. The company is described as a late-stage biopharmaceutical company.

Why it matters — SGP watchers would care because executive participation at these investor conferences could increase the company's visibility with institutional investors and provide an opportunity for management to discuss its late-stage pipeline.

SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

GlobeNewsWire · 6 Aug 2026positive

SpyGlass Pharma reported its second quarter 2026 financial results and provided corporate updates. Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System, with completion expected in 2027, and the Bimatoprost Drug Ring System first-in-human trial is on track to start in the second half of 2026.

Why it matters — SGP watchers would care because the company confirmed its key clinical programs remain on schedule, with the Phase 3 BIM-IOL System trial projected to complete enrollment in 2027 and the BIM-DRS first-in-human trial slated to begin in late 2026.

FAQ

Frequently asked questions about SGP stock

What is the SGP stock price forecast for 2026-2027?

The 6 Wall Street analysts covering SpyGlass Pharma, Inc. have a median 12-month price target of $42, with estimates ranging from $37 to $62. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SGP stock a buy right now?

Of the 6 analysts covering SpyGlass Pharma, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SpyGlass Pharma, Inc. 3 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SGP?

As at 4 Nov 2026, SpyGlass Pharma, Inc. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (48 of 100).

Will SGP stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +21.9% from the last close, and Ticker Nerd's factor model ranks SpyGlass Pharma, Inc. 3 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SGP stock forecast for 2030?

No analyst covering SpyGlass Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SGP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $37 to $62 over the next 12 months.

What does SpyGlass Pharma, Inc. do?

SpyGlass Pharma Inc. is a biopharmaceutical company focused on drug delivery solutions for chronic eye conditions.

What is the latest news on SGP?

The most recent item we track (GlobeNewsWire, 19 Oct 2026): "SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System". SpyGlass Pharma reported positive four-year results from its first-in-human trial of the BIM-IOL System in patients with mild-to-moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery. The company reported a 37% mean IOP reduction, 86% of patients remaining off topical IOP-lowering drops, 90% maintaining at least 20/25 visual acuity, and no product-related adverse events.

Company

About SpyGlass Pharma, Inc.

SpyGlass Pharma Inc. is a biopharmaceutical company focused on drug delivery solutions for chronic eye conditions. The company develops sustained-release ophthalmic products designed to deliver approved medicines in a controlled manner, with an emphasis on treating glaucoma and elevated intraocular pressure. Its lead programs include a drug-pad intraocular lens system intended for use during routine cataract surgery and a non-IOL implant option for patients who are not undergoing cataract surgery. SpyGlass Pharma Inc. works at the intersection of ophthalmology and device-based drug delivery, aiming to improve how long-acting eye treatments are administered in clinical practice. Based in Aliso Viejo, California, the company serves the healthcare and biotechnology markets through products that integrate therapeutic medicine with implantable delivery technology.

CEO Mr. Patrick H. Mooney · 76 employees · United States · https://www.spyglasspharma.com